Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic myelogenous leukemia.

× No keyword cloud information.

12 in total

1. Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.

Authors: Sandra C Dos Santos; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal: OMICS Date: 2012-07-09

2. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.

Authors: Kim Dalziel; Ali Round; Ruth Garside; Ken Stein
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

Review 3. Emerging role of exosomes in hematological malignancies.

Authors: Sureshbabu Ram Kumar Pandian; Kevin Kumar Vijayakumar; Selvaraj Kunjiappan; Ewa Babkiewicz; Piotr Maszczyk
Journal: Clin Exp Med Date: 2022-07-07 Impact factor: 3.984

Review 4. Imatinib: a review of its use in chronic myeloid leukaemia.

Authors: Marit D Moen; Kate McKeage; Greg L Plosker; M Asif A Siddiqui
Journal: Drugs Date: 2007 Impact factor: 9.546

5. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.

Authors: Siddhartha Jaiswal; David Traver; Toshihiro Miyamoto; Koichi Akashi; Eric Lagasse; Irving L Weissman
Journal: Proc Natl Acad Sci U S A Date: 2003-07-30 Impact factor: 11.205

6. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.

Authors: Yiming Chen; Haijun Wang; Hagop Kantarjian; Jorge Cortes
Journal: Leuk Lymphoma Date: 2012-12-05

Review 7. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

Authors: Samuel J Klempner; Andrea P Myers; Gordon B Mills; Shannon N Westin
Journal: Expert Opin Pharmacother Date: 2013-08-12 Impact factor: 3.889

8. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Authors: Chie Hirayama; Hiroshi Watanabe; Reiko Nakashima; Takeru Nanbu; Akinobu Hamada; Akihiko Kuniyasu; Hitoshi Nakayama; Tatsuya Kawaguchi; Hideyuki Saito
Journal: Pharm Res Date: 2007-10-13 Impact factor: 4.200

Review 9. Suboptimal responses in chronic myeloid leukemia: implications and management strategies.

Authors: Elias Jabbour; Giuseppe Saglio; Timothy P Hughes; Hagop Kantarjian
Journal: Cancer Date: 2011-10-28 Impact factor: 6.860

10. Carbenoxolone induces apoptosis and inhibits survivin and survivin-ΔEx3 genes expression in human leukemia K562 cells.

Authors: M A Moosavi; S Moasses Ghafary; I Asvadi-Kermani; H Hamzeiy; M Rahmati; A H Ahmadi; A Nikanfar; Z Sanaat; M Asadi-Khiavi
Journal: Daru Date: 2011 Impact factor: 3.117